News | October 12, 2025
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Several technologies for hemoglobinopathies are being transferred to commercial partners
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Subscribe To Our Newsletter & Stay Updated
